Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease.
作者信息
Onofrj M, Paci C, Thomas A
出版信息
J Neurol Neurosurg Psychiatry. 1998 Oct;65(4):605-6. doi: 10.1136/jnnp.65.4.605.
Abstract
摘要
相似文献
1
Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease.在两名未经多巴胺模拟药物治疗的IV期帕金森病患者中，左旋多巴引入后突然出现无效性运动障碍-肌张力障碍和症状波动。
J Neurol Neurosurg Psychiatry. 1998 Oct;65(4):605-6. doi: 10.1136/jnnp.65.4.605.
2
Rating scales for dyskinesias in Parkinson's disease.帕金森病异动症的评定量表。
Mov Disord. 1999;14 Suppl 1:48-53.
3
The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.帕金森病中左旋多巴诱发异动症的现象学
Mov Disord. 1999;14 Suppl 1:13-8.
4
Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.帕金森病患者左旋多巴诱导的异动症概况：一项基于记录的研究。
Neurol Res. 2014 Sep;36(9):841-6. doi: 10.1179/1743132814Y.0000000339. Epub 2014 Mar 7.
5
Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.足肌张力障碍预示帕金森病左旋多巴诱导的异动症
Clin Neurol Neurosurg. 2013 Feb;115(2):235-6. doi: 10.1016/j.clineuro.2012.05.016. Epub 2012 Jun 27.
6
A Web Resource for Levodopa-Induced Dyskinesia Genetics in Parkinson's Disease.帕金森病中左旋多巴诱发异动症遗传学的网络资源。
Neuroinformatics. 2017 Jul;15(3):297-300. doi: 10.1007/s12021-017-9327-z.
7
Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?帕金森病中左旋多巴诱发的异动症：敏化作用是否可逆？
Ann Neurol. 2000 May;47(5):655-8.
8
[Secondary effects of chronic treatment with levodopa in Parkinson disease].[左旋多巴长期治疗帕金森病的继发效应]
Rev Med Chir Soc Med Nat Iasi. 2003 Jan-Mar;107(1):131-5.
9
Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations.帕金森病中的运动波动和异动症：临床表现
Mov Disord. 2005;20 Suppl 11:S11-6. doi: 10.1002/mds.20458.
10
Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.缓释金刚烷胺（Gocovri）用于治疗帕金森病的运动障碍。
Med Lett Drugs Ther. 2017 Dec 4;59(1535):198-200.
引用本文的文献
1
Analysis of factors associated with brittle response in patients with Parkinson's disease.分析帕金森病患者脆性反应相关因素。
Ann Clin Transl Neurol. 2020 May;7(5):677-682. doi: 10.1002/acn3.51028. Epub 2020 Apr 30.
2
Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.纹状体多巴胺神经元的提前耗竭决定了左旋多巴诱导的帕金森病异动症的发病时间。
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):423-431. doi: 10.1007/s00259-017-3844-8. Epub 2017 Oct 26.
3
Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease.帕金森病左旋多巴诱导的异动症的外科治疗
Ann Indian Acad Neurol. 2017 Jul-Sep;20(3):199-206. doi: 10.4103/aian.AIAN_244_17.
4
The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.帕金森病左旋多巴治疗前的现代时期：来自撒哈拉以南非洲地区对运动并发症的见解。
Brain. 2014 Oct;137(Pt 10):2731-42. doi: 10.1093/brain/awu195. Epub 2014 Jul 17.
5
Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation.纹状体信号在左旋多巴诱导的运动障碍中的作用：涉及 D1 多巴胺受体刺激的药物滥用和长期记忆的共同机制。
Front Neuroanat. 2011 Aug 11;5:51. doi: 10.3389/fnana.2011.00051. eCollection 2011.
6
Three year follow up of levodopa plus carbidopa treatment in a prevalent cohort of patients with Parkinson's disease in Hai, Tanzania.坦桑尼亚 HAI 地区帕金森病流行队列患者左旋多巴加卡比多巴治疗的 3 年随访结果。
J Neurol. 2011 Sep;258(9):1649-56. doi: 10.1007/s00415-011-5988-y. Epub 2011 Mar 26.
7
Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?帕金森病中的左旋多巴：神经毒性问题已得到解决？
Drug Saf. 1999 Nov;21(5):339-52. doi: 10.2165/00002018-199921050-00001.
Zotero 插件